Lista de obras - James Campbell - Dominio Público Uruguay

A genetic screen using the PiggyBac transposon in haploid cells identifies Parp1 as a mediator of olaparib toxicity

artículo científico publicado en 2013

A novel strategy using MASCOT Distiller for analysis of cleavable isotope-coded affinity tag data to quantify protein changes in plasma

artículo científico publicado en 2005

ATR Is a Therapeutic Target in Synovial Sarcoma.

artículo científico publicado en 2017

ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A.

artículo científico publicado en 2016

Abstract 5076: Integrative genomic and transcriptomic analysis of metaplastic carcinomas of the breast

article by Alan G. Mackay et al published 15 April 2012 in Cancer Research

Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease

artículo científico publicado en 2010

Author Correction: Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness

artículo científico publicado en 2018

CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours

artículo científico publicado en 2016

CancerGD: A Resource for Identifying and Interpreting Genetic Dependencies in Cancer

artículo científico publicado en 2017

CancerGD: a resource for identifying and interpreting genetic dependencies in cancer

scholarly article published 26 October 2016

Candidate verification of iron-regulated Neisseria meningitidis proteins using isotopic versions of tandem mass tags (TMT) and single reaction monitoring

artículo científico publicado en 2009

Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness

artículo científico publicado en 2018

Comparison of a protein-level and peptide-level labeling strategy for quantitative proteomics of synaptosomes using isobaric tags

artículo científico publicado en 2010

Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours

artículo científico publicado en 2017

Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours

artículo científico publicado en 2016

Correction: Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours

artículo científico publicado en 2018

Coupling bimolecular PARylation biosensors with genetic screens to identify PARylation targets.

artículo científico publicado en 2018

E-Cadherin/ROS1 Inhibitor Synthetic Lethality in Breast Cancer.

artículo científico publicado en 2018

Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study

artículo científico

Elevated APOBEC3B expression drives a kataegic-like mutation signature and replication stress-related therapeutic vulnerabilities in p53-defective cells

artículo científico publicado en 2017

Evaluation of CDK12 Protein Expression as a Potential Novel Biomarker for DNA Damage Response-Targeted Therapies in Breast Cancer.

artículo científico publicado en 2017

Evaluation of absolute peptide quantitation strategies using selected reaction monitoring

artículo científico publicado en 2011

Exome Sequencing of an Adult Pituitary Atypical Teratoid Rhabdoid Tumor

artículo científico publicado en 2015

Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance.

artículo científico publicado en 2018

Genome-wide barcoded transposon screen for cancer drug sensitivity in haploid mouse embryonic stem cells

artículo científico publicado en 2017

Genome-wide characterization reveals complex interplay between TP53 and TP63 in response to genotoxic stress

artículo científico publicado en 2014

Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity

artículo científico publicado en 2014

High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial

scientific article published on 13 May 2016

Identification of highly penetrant Rb-related synthetic lethal interactions in triple negative breast cancer

scientific article published on 18 June 2018

Identifying Genetic Dependencies in Cancer by Analyzing siRNA Screens in Tumor Cell Line Panels

artículo científico publicado en 2018

Large-Scale Profiling of Kinase Dependencies in Cancer Cell Lines

artículo científico publicado en 2016

Mapping genetic vulnerabilities reveals BTK as a novel therapeutic target in oesophageal cancer

artículo científico publicado en 2017

Modeling Therapy Resistance in BRCA1/2-Mutant Cancers

artículo científico publicado en 2017

Optimised ARID1A immunohistochemistry is an accurate predictor of ARID1A mutational status in gynaecological cancers.

artículo científico publicado en 2018

Parallel RNA interference screens identify EGFR activation as an escape mechanism in FGFR3-mutant cancer ⬇️

artículo científico publicado en 2013

Pharmacoproteomic investigation into antidepressant response in two mouse inbred strains

artículo científico publicado en 2012

Plasma biomarkers of brain atrophy in Alzheimer's disease

artículo científico publicado en 2011

Plasma gelsolin is decreased and correlates with rate of decline in Alzheimer's disease

artículo científico publicado en 2010

Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer

artículo científico publicado en 2013

Proteome-based plasma markers of brain amyloid-β deposition in non-demented older individuals

artículo científico publicado en 2010

Proteomics for brain disorders--the promise for biomarkers

artículo científico publicado en 2009

Secondary mutations inBRCA2associated with clinical resistance to a PARP inhibitor

article by Louise J Barber et al published 25 January 2013 in Journal of Pathology

Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib

artículo científico publicado en 2016

The genomic landscape of oesophagogastric junctional adenocarcinoma

artículo científico publicado en 2013

Therapeutic vulnerabilities in the DNA damage response for the treatment of ATRX mutant neuroblastoma

artículo científico publicado en 2020

Three-dimensional modelling identifies novel genetic dependencies associated with breast cancer progression in the isogenic MCF10 model

artículo científico publicado en 2016

Unbiased analysis of potential targets of breast cancer susceptibility loci by Capture Hi-C.

artículo científico publicado en 2014

Whole-exome DNA sequence analysis of Brca2- and Trp53-deficient mouse mammary gland tumours

artículo científico publicado en 2015

Lista de obras de James Campbell

A genetic screen using the PiggyBac transposon in haploid cells identifies Parp1 as a mediator of olaparib toxicity

A novel strategy using MASCOT Distiller for analysis of cleavable isotope-coded affinity tag data to quantify protein changes in plasma

ATR Is a Therapeutic Target in Synovial Sarcoma.

ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A.

Abstract 5076: Integrative genomic and transcriptomic analysis of metaplastic carcinomas of the breast

Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease

Author Correction: Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness

CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours

CancerGD: A Resource for Identifying and Interpreting Genetic Dependencies in Cancer

CancerGD: a resource for identifying and interpreting genetic dependencies in cancer

Candidate verification of iron-regulated Neisseria meningitidis proteins using isotopic versions of tandem mass tags (TMT) and single reaction monitoring

Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness

Comparison of a protein-level and peptide-level labeling strategy for quantitative proteomics of synaptosomes using isobaric tags

Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours

Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours

Correction: Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours

Coupling bimolecular PARylation biosensors with genetic screens to identify PARylation targets.

E-Cadherin/ROS1 Inhibitor Synthetic Lethality in Breast Cancer.

Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study

Elevated APOBEC3B expression drives a kataegic-like mutation signature and replication stress-related therapeutic vulnerabilities in p53-defective cells

Evaluation of CDK12 Protein Expression as a Potential Novel Biomarker for DNA Damage Response-Targeted Therapies in Breast Cancer.

Evaluation of absolute peptide quantitation strategies using selected reaction monitoring

Exome Sequencing of an Adult Pituitary Atypical Teratoid Rhabdoid Tumor

Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance.

Genome-wide barcoded transposon screen for cancer drug sensitivity in haploid mouse embryonic stem cells

Genome-wide characterization reveals complex interplay between TP53 and TP63 in response to genotoxic stress

Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity

High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial

Identification of highly penetrant Rb-related synthetic lethal interactions in triple negative breast cancer

Identifying Genetic Dependencies in Cancer by Analyzing siRNA Screens in Tumor Cell Line Panels

Large-Scale Profiling of Kinase Dependencies in Cancer Cell Lines

Mapping genetic vulnerabilities reveals BTK as a novel therapeutic target in oesophageal cancer

Modeling Therapy Resistance in BRCA1/2-Mutant Cancers

Optimised ARID1A immunohistochemistry is an accurate predictor of ARID1A mutational status in gynaecological cancers.

Parallel RNA interference screens identify EGFR activation as an escape mechanism in FGFR3-mutant cancer ⬇️

Pharmacoproteomic investigation into antidepressant response in two mouse inbred strains

Plasma biomarkers of brain atrophy in Alzheimer's disease

Plasma gelsolin is decreased and correlates with rate of decline in Alzheimer's disease

Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer

Proteome-based plasma markers of brain amyloid-β deposition in non-demented older individuals

Proteomics for brain disorders--the promise for biomarkers

Secondary mutations inBRCA2associated with clinical resistance to a PARP inhibitor

Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib

The genomic landscape of oesophagogastric junctional adenocarcinoma

Therapeutic vulnerabilities in the DNA damage response for the treatment of ATRX mutant neuroblastoma

Three-dimensional modelling identifies novel genetic dependencies associated with breast cancer progression in the isogenic MCF10 model

Unbiased analysis of potential targets of breast cancer susceptibility loci by Capture Hi-C.

Whole-exome DNA sequence analysis of Brca2- and Trp53-deficient mouse mammary gland tumours